MARKET

ATXS

ATXS

Astria Therapeutics Inc
NASDAQ
13.09
+0.10
+0.77%
After Hours: 13.09 0 0.00% 16:10 12/31 EST
OPEN
13.00
PREV CLOSE
12.99
HIGH
13.13
LOW
12.97
VOLUME
301.52K
TURNOVER
--
52 WEEK HIGH
13.29
52 WEEK LOW
3.555
MARKET CAP
747.24M
P/E (TTM)
-6.1223
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATXS last week (1222-1226)?
Weekly Report · 12/29/2025 10:19
Astria Faces Shareholder Lawsuits Over Planned BioCryst Merger
TipRanks · 12/23/2025 22:55
Astria Therapeutics Says Complaints Filed Against Astria In New York Supreme Court; Complaints Allege Negligence & Negligent Misrepresentation & Concealment Against Astria & Board; Believes That Claims Asserted In Complaints Are Without Merit
Benzinga · 12/23/2025 22:31
ASTRIA THERAPEUTICS INC - COMPLAINTS FILED AGAINST ASTRIA IN NEW YORK SUPREME COURT - SEC FILING
Reuters · 12/23/2025 22:27
ASTRIA THERAPEUTICS INC: BELIEVES THAT CLAIMS ASSERTED IN COMPLAINTS ARE WITHOUT MERIT
Reuters · 12/23/2025 22:27
Astria Therapeutics to Be Acquired by BioCryst Pharmaceuticals
Reuters · 12/23/2025 22:16
Weekly Report: what happened at ATXS last week (1215-1219)?
Weekly Report · 12/22/2025 10:19
Weekly Report: what happened at ATXS last week (1208-1212)?
Weekly Report · 12/15/2025 10:27
More
About ATXS
Astria Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases. Its lead product candidate is Navenibart, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, autosomal dominant genetic disorder. Its second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis (AD), an immune disorder associated with loss of skin barrier function and itching. It owns five patent families directed to navenibart. The first patent family is directed to the composition of matter of navenibart and its use in treating various plasma kallikrein associated disorders, including HAE. In the second patent family, it is directed to methods of treating various plasma-kallikrein-associated disorders, including HAE.

Webull offers Astria Therapeutics Inc stock information, including NASDAQ: ATXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATXS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATXS stock methods without spending real money on the virtual paper trading platform.